Abbott and Tandem Diabetes Care are partnering to develop integrated diabetes solutions. The companies will combine Abbott’s continuous glucose monitoring (CGM) technology with Tandem’s insulin delivery systems.
Tandem’s t:slim X2 was the first alternate controller enabled (ACE) infusion insulin pump to be cleared by the US Food and Drug Administration (FDA) in 2019. ACE pumps allow for reliable and secure communication with compatible external devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The t:slim X2 software can be remotely updated so that users can access new features as they become available.
Abbott’s FreeStyle Libre is the world’s leading sensor-based CGM system by number of users but is not currently indicated for use with automatic insulin delivery systems. Abbott and Tandem will connect their technologies for future automated insulin delivery systems, providing options for users to tailor and simplify how they manage their diabetes.
“By combining our glucose sensing technology with Tandem’s proven insulin delivery systems, we will be able to create a cohesive ecosystem for people with diabetes that can fit easily into their daily lives” said Jared Watkin, senior vice president, Diabetes Care, Abbott.
The combined solution will initially be available in the US and Canada.